Reliability and safety of intravitreal Ozurdex injections: The ZERO study;Zuverlässigkeit und Sicherheit von intravitrealen Ozurdex-Injektionen: Die ZERO-Studie

Ophthalmologe

Volumn 111, Issue 1, 2014, Pages 44-52

  Schmitz, K ^a   Maier, M ^b   Clemens, C R ^c   Hohn F ^d   Wachtlin, J ^e   Lehmann, F ^f   Bertelmann, T ^g   Rudiger K ^h   Horn, M ⁱ   Bezatis, A ^j   Spital, G ^a   Meyer, C H ^g,j,k  

^a ST FRANZISKUS HOSPITAL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d KLINIKUM LUDWIGSHAFEN   (Germany)

^e MARTIN LUTHER KRANKENHAUS   (Germany)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h KLINIKUM DORTMUND   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^j UNIVERSITY OF BONN   (Germany)

^k Klinik Pallas   (Switzerland)

more..

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Macular edema; Ozurdex; Retinal vein occlusion

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXAMETHASONE; DRUG IMPLANT;

ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG IMPLANT; ENDOPHTHALMITIS; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MULTICENTER STUDY; OCULAR HYPERTENSION; RETINAL VEIN OCCLUSION; RETROGNATHIA; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DRUG IMPLANTS; ENDOPHTHALMITIS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; OCULAR HYPERTENSION; RETINAL VEIN OCCLUSION; RETROGNATHIA; TREATMENT OUTCOME;

EID: 84893693532     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-012-2737-2     Document Type: Article

References (44)

1. Rogers S, McIntosh RL, Cheung N et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313-319
2. Klein R, Moss SE, Meuer SM, Klein BE (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 126:513-518
3. Ritch R, Prata TS, Moraes CG de et al (2010) Association of exfoliation syndrome and central retinal vein occlusion: an ultrastructural analysis. Acta Ophthalmol 88:91-95
4. Koss MJ, Pfister M, Rothweiler F et al (2012) Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 90:98-103
5. Stahl A, Buchwald A, Martin G et al (2010) Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina 30:1524-1529
6. Feltgen N, Pielen A, Hansen L et al (2010) Intravitreal drug therapy for retinal vein occlusion-pathophysiological mechanisms and routinely used drugs. Klin Monatsbl Augenheilkd 227:681-693
7. Lang GE (2011) New developments in the pharmacological treatment of macular oedema due to retinal vein occlusion. Klin Monatsbl Augenheilkd 228:793-800
8. Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124-1133
9. Jaissle GB, Szurman P, Feltgen N et al (2010) Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249:183-192
10. Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102-1112
11. Haller JA, Bandello F, Belfort R Jr et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134-1146
12. Bezatis T, Meyer CH (2011) Erste Ergebnisse nach Ozurdex-Injektionen bei retinalen Gefässverschlüssen. Z Prakt Augenheilkd 32:417-422
13. Parodi MB, Iacono P, Cascavilla M et al (2012) Compassionate use of dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion in a clinical setting. Acta Ophthalmol 90:322-323
14. Bezatis A, Spital G, Höhn F et al (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-months follow-up study. The SOLO-Study. Acta Ophthalmol (angenommen)
15. German Ophthalmological Society; Retinological Society; Professional Association of German Ophthalmologists (2010) Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists on therapy for macular oedema in cases of retinal vein occlusion. Klin Monatsbl Augenheilkd 227:542-556
16. Rodrigues EB, Grumann A, Penha FM et al (2011) Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther 27:197-203
17. Meyer CH, Klein A, Alten F et al (2012) Release and velocity of micronized dexamethasone intravitreal implants with an intravitreal drug delivery system-kinematic analysis with a high-speed camera. Retina 32:2133-2140
18. Mirshahi A, Lorenz K, Kramann C et al (2011) Ophthalmologic diagnostic procedures and imaging of retinal vein occlusions. Ophthalmologe 108:111-116
19. Helb HM, Charbel Issa P, Fleckenstein M et al (2010) Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol 88:842-849
20. Ach T, Hoeh AE, Schaal KB et al (2010) Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 248:155-159
21. Westfall AC, Osborn A, Kuhl D et al (2005) Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 123:1075-1077
22. Goldberg RA, Flynn HW Jr, Isom RF et al (2012) An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 153:204-208
23. Ness T, Feltgen N, Agostini H et al (2010) Toxic vitreitis outbreak after intravitreal injection. Retina 30:332-338
24. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr et al (2011) Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 31:662-668
25. Mennel S, Meyer CH, Eter N (2007) Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application. Ophthalmologe 104:952-957
26. Bhatt SS, Stepien KE, Joshi K (2011) Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina 31:2032-2036
27. Cheung CS, Wong AW, Lui A et al (2012) Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 119(8):1609-1614
28. Meyer CH, Rodrigues EB, Michels S et al (2010) Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 26:491-495
29. Meyer CH, Michels S, Rodrigues EB, Hager A et al (2011) Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 89:70-75
30. Koller S, Neuhann T, Neuhann I (2012) Auffälliger Linsenfremdkörper nach intravitrealer Injektion-In die natürliche Augenlinse fehlimplantiertes Ozurdex®-Pellet. Ophthalmologe 109:1119-1121
31. Roth DB, Verma V, Realini T et al (2009) Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 116:455-460
32. Lau LI, Chen KC, Lee FL et al (2008) Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol 146:573-578
33. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM (2008) Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246:955-958
34. Choi DY, Ortube MC, McCannel CA et al (2011) Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 31:1028-1035
35. Bansal R, Bansal P, Kulkarni P et al (2012) Wandering Ozurdex(®) implant. J Ophthalmic Inflamm Infect 2:1-5
36. Pardo-López D, Francés-Muñoz E, Gallego-Pinazo R, Díaz-Llopis M (2012) Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol 250:1704-04
37. Bakri SJ, Omar AF (2012) Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther 28:547-549
38. Bertelmann T, Kičová N, Messerschmidt-Roth A et al (2011) The vitreomacular interface in retinal vein occlusion. Acta Ophthalmol 89:327-331
39. Guthoff R, Meigen T, Hennemann K, Schrader W (2010) Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica 224:319-324
40. Meyer CH, Krohne TU, Holz FG (2011) Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 31:1877-1884
41. Krohne TU, Liu Z, Holz FG, Meyer CH (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682-686
42. Kim H, Csaky KG, Gravlin L et al (2006) Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina 26:523-530
43. Kamppeter BA, Cej A, Jonas JB (2008) Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. Ophthalmology 115:1372-1375
44. Chang-Lin JE, Attar M, Acheampong AA et al (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80-86